Basic information Safety Supplier Related

BLU-285

Basic information Safety Supplier Related

BLU-285 Basic information

Product Name:
BLU-285
Synonyms:
  • Avapritinib(BLU-285)
  • BLU-285
  • CPD1212
  • Avapritinib
  • (1S)-1-(4-Fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl}-5-pyrimidinyl)ethanamine
  • BLU-285 (Avapritinib)
  • BLU-285;BLU 285;BLU285
  • CS-2474
CAS:
1703793-34-3
MF:
C26H27FN10
MW:
498.56
Product Categories:
  • API
Mol File:
1703793-34-3.mol
More
Less

BLU-285 Chemical Properties

Density 
1.42±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO:83.11(Max Conc. mg/mL);166.7(Max Conc. mM)
form 
A crystalline solid
pka
6.96±0.10(Predicted)
CAS DataBase Reference
1703793-34-3
More
Less

BLU-285 Usage And Synthesis

Description

BLU-285 is a dual inhibitor of KIT receptor and platelet-derived growth factor receptor α (PDGFRα) tyrosine kinases with activating loop mutations (IC50s = 0.27 and 0.24 nM for KITD816V and PDGFRαD842V, respectively). It is >150-fold selective for KITD816V and PDGFRαD842V over a kinase panel at a concentration of 3 μM. BLU-285 also has activity against a panel of KIT and PDGFRα loop mutants identified in patients with gastrointestinal stromal tumors (GISTs; IC50s = <100 nM). It inhibits growth of cancer cell lines containing wild-type and mutant KIT and PDGFRα, demonstrating increased potency in cell lines expressing KIT and PDGFRα with activating loop mutations. BLU-285 (0.3-30 mg/kg) reduces tumor volume in a P815 KITD814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner. Formulations containing BLU-285 have been used to treat KIT- and PDGFRα-driven malignancies.

Uses

Avapritinib is a medication used for the treatment of tumors due to one specific rare mutation. Avapritinib is a potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor.

Indications

Avapritinib is approved for the treatment of adult patients with unresectable or metastatic gastrointestinal mesenchymal stromal tumour (GIST) carrying platelet-derived growth factor receptor A (PDGFRA) exon 18 mutations, including the D842V mutation, as well as adult patients with advanced systemic mastocytosis (ASM).

brand name

Ayvakit

General Description

Class: receptor tyrosine kinase; Treatment: GIST, SM; Other name: BLU-285; Elimination half-life = 32–57 h; Protein binding = 98.8%

target

Primary targets: PDGFRA, KIT

BLU-285Supplier

ShangHai Caerulum Pharma Discovery Co., Ltd. Gold
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
ShangHai ChuanQian Chemcial Technique Centre Gold
Tel
15869524721
Email
3525679403@qq.com
Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd Gold
Tel
15317229551
Email
15151849396@163.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
More
Less

BLU-285(1703793-34-3)Related Product Information